Paraguay's pharma industry seeks to rebound after pandemic

25 June 2021

The pharmaceutical industry in Paraguay – comprising of domestic drugmakers and multinationals with a presence in the country – is expected to grow by at least 5% in 2021, writes The Pharma Letter’s Latin American correspondent.

Growth will be driven by demand for COVID-19 vaccines along with ivermectin and other drugs to treat the virus, according to IQVIA.

This follows a year in which some companies have been particularly hard hit, particularly those without products for COVID-19. Prescription drugs for chronic diseases, flu and cough were among the most affected, with painkillers a rare exception in recording sales growth, IQVIA research shows.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK